European Medicines Agency: "AZ Vaccine Linked to Liver Thrombosis"

[Image source=Reuters Yonhap News]

[Asia Economy Reporter Jeong Hyunjin] A senior official from the European Medicines Agency (EMA) made remarks suggesting a causal relationship between the COVID-19 vaccine developed by the multinational pharmaceutical company AstraZeneca (AZ) and the University of Oxford in the UK and thrombosis.

According to AFP and others on the 6th (local time), Marco Cavaleri, head of vaccine strategy at EMA, said in an interview with the Italian daily Il Messaggero published that day, "It is becoming increasingly difficult to say that there is no causal relationship between the AZ vaccine and the very rare reported unusual thrombosis."

Cavaleri explained, "In my opinion, it is clear that (this symptom) is related to the vaccine," but added, "We still do not know what causes this reaction." He further stated, "We (EMA) will clarify this within the next few hours."

Cavaleri also said, "We are currently trying to accurately understand what is happening and to define this syndrome related to the vaccine in detail," adding, "It is still a long way before this evaluation work is completed."

EMA announced the safety evaluation results of the AZ vaccine on the 18th of last month. At that time, EMA stated that there was no association between the AZ vaccine and an increased risk of common thrombosis but could not completely exclude a causal relationship with very rare reported specific thrombosis and was conducting additional evaluations. However, concerns about safety have continued as cases of thrombosis have persisted since then.

This content was produced with the assistance of AI translation services.